Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort.
Paulina Szafors, Cedric Lukas, Bernard Combe...
https://pubmed.ncbi.nlm.nih.gov/42384910/Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2020-03-13
395
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are conducting a national multi-center prospective cohort study called ASSESS to evaluate patients with Primary Sjgrens Syndrome pSS, a systemic autoimmune disease affecting about 0.1% of the population. This condition causes symptoms like disabling dryness, fatigue, pain, and systemic complications in roughly 30% of patients, including issues affecting skin, joints, lungs, kidneys, nerves, muscles, and blood vessels. The study aims to assess the evolution of pSS and identify factors that predict systemic complications and lymphoma over a 20-year follow-up period. Participants are patients with Primary Sjgrens Syndrome who have already taken part in the initial ASSESS study. Over 20 years, clinicians annually collect detailed data using standardized case report forms about systemic complications, lymphoma occurrence, and other health outcomes. No experimental treatments are given instead, patient data is gathered during routine disease follow-up visits. Throughout the study, participants undergo regular evaluations that include clinical assessments recorded with tools such as the European League Against Rheumatism EULAR Sjgren Syndrome Disease Activity Index ESSDAI and the Patient Reported Index ESSPRI. Researchers monitor the number and variation of systemic complications, lymphoma development, cancers, cardiovascular events, medications used, and blood test results. The long-term follow-up ensures comprehensive monitoring of disease progression and related health issues.
CONDITIONS
The ASSESS National Multi-center Prospective Cohort
X
Xavier Mariette
J
Jacques-Eric Gottenberg
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
Societe Francaise de Rhumatologie
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 20 years
Participants with Primary Sjögren's Syndrome are observed to assess systemic complications, disease evolution, and development of lymphoma and other conditions over time.
Regular visits during the 20-year follow-up period
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Paulina Szafors, Cedric Lukas, Bernard Combe...
https://pubmed.ncbi.nlm.nih.gov/42384910/Pierre-Marie Duret, Cedric Schleiss, Lou Kawka...
https://pubmed.ncbi.nlm.nih.gov/37115807/Assistance Publique - Hôpitaux de Paris
Lead Sponsor
Societe Francaise de Rhumatologie
Collaborating Sponsor